金融调研｜穿越生物制药“死亡之谷”，科技金融如何全周期护航？

Group 1 - The biopharmaceutical industry faces a "valley of death" challenge, with only about 10% of drugs surviving from research to market approval, a process that can take over 10 years [1] - Traditional credit logic does not align with the characteristics of the biopharmaceutical sector, which is asset-light and heavily reliant on R&D, necessitating innovative financial support for tech-driven SMEs [2][4] - Financial institutions are developing differentiated financial support paths, focusing on early, small, long-term investments in hard technology to facilitate innovation and technology transfer in biomedicine [2][8] Group 2 - Kanglin Biotechnology, established in 2015, is a representative case of a company facing funding challenges despite having core technology in gene therapy for thalassemia [3] - The company has successfully addressed significant technical challenges in gene therapy, with clinical trial data showing rapid recovery in treated patients [5] - The financial support from banks, including credit loans and equity investments, has been crucial for Kanglin Biotechnology to progress through various stages of R&D and clinical trials [4][5] Group 3 - Many university biomedicine projects remain in the laboratory stage, facing difficulties in securing social capital due to high risks and long timelines [6][7] - A new financial support system has been established to facilitate the transformation of academic research into commercial applications, including early-stage funding and customized financial products [7][8] - The integration of finance and technology is transforming the "valley of death" into a "growth fertile land," with significant funding and project conversions achieved [8] Group 4 - The current landscape of technology finance is marked by intensified competition among banks, necessitating collaborative support for the diverse financial needs of tech companies [9] - Commercial banks are innovating their services to provide comprehensive support, including non-financial services like site selection and equity financing [9] - Future efforts will focus on developing risk-sharing systems and insurance products to enhance the resilience of technology transfer against potential risks [10]